Comparative Pharmacology
Head-to-head clinical analysis: FORBAXIN versus KETEK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORBAXIN versus KETEK.
FORBAXIN vs KETEK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Telithromycin binds to the 50S subunit of bacterial ribosome, inhibiting protein synthesis by blocking peptide chain elongation.
IV: 500 mg every 12 hours, infused over 30 minutes.
Telithromycin 800 mg orally once daily for 7-10 days.
None Documented
None Documented
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Terminal half-life (t½) is 9.8–10.6 hours in young healthy adults, allowing once-daily dosing. In elderly or severe hepatic impairment, t½ may be prolonged.
Renal (60-70% unchanged), biliary/fecal (20-30%)
Primarily fecal (≈70%) via biliary excretion of unchanged drug; renal excretion accounts for ≈13% (mostly unchanged), with additional minor metabolism (<30%).
Category C
Category C
Antibiotic
Antibiotic, Ketolide